HOW TO GET
NERLYNX
SUPPORT CO-PAY
CARD
REQUEST
CONTACT

This site is intended for healthcare professionals.
Prescribing Information For patients, click here.

MENU
Now Approved

For HER2+ early stage breast cancer,
NERLYNX in the extended adjuvant setting is your
new opportunity to further reduce the risk of recurrence

NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of
adult patients with early-stage HER2 overexpressed/amplified breast cancer,
to follow adjuvant trastuzumab-based therapy.

EXPLORE THE NERLYNX PRESCRIBING INFORMATION

Prescribing Information

From the indication to clinical studies,
read through the Prescribing Information.

View PDF »

How to get NERLYNX

Access our Reimbursement Form and view our Specialty Pharmacy List.

Click Here »

Patient co-pay card

See how we assist patients with their NERLYNX prescription.

Learn More »

REQUEST CONTACT

Request to be contacted by a NERLYNX sales representative or a Clinical Nurse Educator (CNE)

Go »

IMPORTANT SAFETY INFORMATION

NERLYNX (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS: The most common adverse reactions (≥ 5%) were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased and urinary tract infection.

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) and www.NERLYNX.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

For Full Prescribing Information, please click here.